A recent Free News article discussed the latest mRNA development from Moderna, maker of one of the main COVID-19 vaccines. Apparently the company has two experimental HIV vaccines in work that are expected to begin clinical trials before the end of the year. The vaccines, Moderna mRNA-1644 and mRNA-1644v2-Core, have both passed phase I testing.
The next phase of trials will be conducted with 56 adults ages 18 to 50, some of whom will be infected with the human immunodeficiency virus. Moderna is hoping the novel vaccines will see the same success as their mRNA-1273 COVID-19 vaccine, which is expected to sell $20 billion this year.
